Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Labeling for Pediatric MRI

Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug Administration (FDA) approval for an extension to include magnetic resonance imaging (MRI) of the central nervous system (CNS) in pediatric patients younger than 2 years of age (including term neonates). The agent may now be used in this patient population to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.

Bracco's MultiHance to Show Improved MR Visualization

A liposomal Gd contrast agent does not cross the mouse placental barrier

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

The Use of Contrast-enhanced MRI in At-risk Patient Populations • APPLIED RADIOLOGY

FDA approves Bracco's ProHance for use in kids

Considerations in the Selection of a New Gadolinium-Based Contrast Agent • APPLIED RADIOLOGY

Contrast-enhanced Magnetic Resonance Imaging in Pediatric Patients: Review and Recommendations for Current Practice - Ravi Bhargava, Gabriele Hahn, Wolfgang Hirsch, Myung-Joon Kim, Hans-Joachim Mentzel, Øystein E. Olsen, Eira Stokland, Fabio Triulzi, Elida

PDF) The utility of gadoteric acid in contrast-enhanced MRI: A review

Use of Eovist in Pediatric Patients: Pearls and Pitfalls - ScienceDirect

Bracco's MultiHance to Show Improved MR Visualization

FDA approves Bracco's contrast agent for pediatric CNS imaging - MassDevice

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

Imaging Technology News - Magnetic Resonance Imaging (MRI)